Curis (CRIS) Cyclically Adjusted PS Ratio: (As of Aug. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CRIS Curis Inc CRIS
53 GF Score
Price $4.51
GF Value $1.45
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Curis Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Curis  (NAS:CRIS) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Curis Cyclically Adjusted PS Ratio Related Terms


Curis Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Curis's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curis Cyclically Adjusted PS Ratio Chart

Curis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.46 0.06 0.10 0.03 0.01

Curis Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 0.02 0.01 0.00

CRIS vs ASBP, VTGN, TOVX: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Curis's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Curis Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Curis's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Curis's Cyclically Adjusted PS Ratio falls into.


CRIS
53GF Score
Curis Inc CRIS
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Curis Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Curis's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Curis's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0/330.2130*330.2130
=0.000

Current CPI (Mar. 2026) = 330.2130.

Curis Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 25.846 241.018 35.411
201609 26.652 241.428 36.453
201612 33.743 241.432 46.151
201703 30.014 243.801 40.652
201706 28.625 244.955 38.588
201709 33.479 246.819 44.791
201712 39.780 246.524 53.284
201803 29.735 249.554 39.346
201806 28.410 251.989 37.229
201809 34.301 252.439 44.869
201812 33.193 251.233 43.628
201903 21.289 254.202 27.655
201906 25.229 256.143 32.525
201909 34.410 256.759 44.254
201912 39.602 256.974 50.889
202003 31.500 258.115 40.299
202006 23.838 257.797 30.534
202009 20.162 260.280 25.579
202012 18.327 260.474 23.234
202103 9.559 264.877 11.917
202106 9.983 271.696 12.133
202109 13.271 274.310 15.976
202112 13.690 278.802 16.214
202203 8.983 287.504 10.317
202206 10.450 296.311 11.646
202209 12.073 296.808 13.432
202212 11.979 296.797 13.328
202303 9.492 301.836 10.384
202306 9.079 305.109 9.826
202309 9.906 307.789 10.628
202312 9.329 306.746 10.043
202403 7.218 312.332 7.631
202406 8.749 314.175 9.196
202409 9.869 315.301 10.336
202412 8.711 315.605 9.114
202503 5.600 319.799 5.782
202506 4.357 322.561 4.460
202509 4.051 324.800 4.119
202512 1.442 324.054 1.469
202603 0.000 330.213 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Curis (CRIS) Overvalued in 2026?

Based on GuruFocus' analysis, Curis stock appears to be overvalued. The current stock price of $4.51 is trading 211% above its estimated GF Value™ of $1.45. GuruFocus considers Curis to be Significantly Overvalued.

Key valuation signals for CRIS:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: $1.45 vs. price of $4.51 (211% above fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the CRIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Curis Business Description

Other Exchanges CUS0:Germany
Address 128 Spring Street, Building C - Suite 500, Lexington, MA, USA, 02421
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
53GF Score

Get the complete analysis for CRIS

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.51
Price
$1.45
GF Value